Emergence of plasmid-mediated mcr genes from Gram-negative bacteria at the human-animal interface.
Antibacterial profile
Antimicrobial resistance
Colistin resistance
Mobile colistin resistance
Plasmid-mediated resistance
mcr genes
Journal
Gut pathogens
ISSN: 1757-4749
Titre abrégé: Gut Pathog
Pays: England
ID NLM: 101474263
Informations de publication
Date de publication:
20 Nov 2020
20 Nov 2020
Historique:
received:
18
07
2020
accepted:
04
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
The global emergence of plasmid-mediated colistin resistance (Col-R) conferred by mcr genes in gram-negative rods (GNRs) has jeopardized the last treatment option for multidrug-resistant bacterial infections in humans. This study aimed to assess the emergence of mcr gene-mediated Col-R in GNRs isolated from humans and animals in Pakistan. Animal and clinical specimens collected from various sources were prospectively analysed using standard microbiological procedures. Pathogens were identified using the API 20E and API 20NE systems (bioMerieux). Minimum inhibitory concentration (MIC) against colistin was determined using the MIC detection methods, and multiplex polymerase chain reaction (PCR) was used to amplify the mcr-1 to mcr-5 genes. We isolated 126 (88.1%) animal and 17 (11.9%) human Col-R phenotypes, among which there was a significant association (P < 0.01) of Escherichia coli and Proteus mirabilis with animals and of Acinetobacter baumannii with humans. Animal strains exhibited statistically significant (P < 0.05) resistance to co-trimoxazole, chloramphenicol, and moxifloxacin, and the human pathogens exhibited statistically significant (P < 0.05) antibiotic resistance to cephalosporins, carbapenems, and piperacillin-tazobactam. For Col-R strains, MIC The detection of a considerable number of mcr-1 and mcr-2 genes in animals is worrisome, as they are now being detected in clinical pathogens. The acquisition of mcr genes by colistin-susceptible bacteria could leave us in a post-antibiotic era.
Sections du résumé
BACKGROUND
BACKGROUND
The global emergence of plasmid-mediated colistin resistance (Col-R) conferred by mcr genes in gram-negative rods (GNRs) has jeopardized the last treatment option for multidrug-resistant bacterial infections in humans. This study aimed to assess the emergence of mcr gene-mediated Col-R in GNRs isolated from humans and animals in Pakistan.
METHODS
METHODS
Animal and clinical specimens collected from various sources were prospectively analysed using standard microbiological procedures. Pathogens were identified using the API 20E and API 20NE systems (bioMerieux). Minimum inhibitory concentration (MIC) against colistin was determined using the MIC detection methods, and multiplex polymerase chain reaction (PCR) was used to amplify the mcr-1 to mcr-5 genes.
RESULTS
RESULTS
We isolated 126 (88.1%) animal and 17 (11.9%) human Col-R phenotypes, among which there was a significant association (P < 0.01) of Escherichia coli and Proteus mirabilis with animals and of Acinetobacter baumannii with humans. Animal strains exhibited statistically significant (P < 0.05) resistance to co-trimoxazole, chloramphenicol, and moxifloxacin, and the human pathogens exhibited statistically significant (P < 0.05) antibiotic resistance to cephalosporins, carbapenems, and piperacillin-tazobactam. For Col-R strains, MIC
CONCLUSIONS
CONCLUSIONS
The detection of a considerable number of mcr-1 and mcr-2 genes in animals is worrisome, as they are now being detected in clinical pathogens. The acquisition of mcr genes by colistin-susceptible bacteria could leave us in a post-antibiotic era.
Identifiants
pubmed: 33292525
doi: 10.1186/s13099-020-00392-3
pii: 10.1186/s13099-020-00392-3
pmc: PMC7678191
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54Subventions
Organisme : Higher Education Commission, Pakistan
ID : NRPU 8557
Références
Emerg Infect Dis. 2017 Nov;23(11):1872-1875
pubmed: 29048298
Euro Surveill. 2018 Jan;23(2):
pubmed: 29338810
J Antimicrob Chemother. 2016 Aug;71(8):2331-3
pubmed: 27330064
Lancet Infect Dis. 2016 Mar;16(3):285-6
pubmed: 26774239
Gut Pathog. 2019 Jan 31;11:2
pubmed: 30728861
Euro Surveill. 2017 Aug 3;22(31):
pubmed: 28797324
Lancet Infect Dis. 2016 Mar;16(3):293
pubmed: 26973308
Euro Surveill. 2016 Jul 7;21(27):
pubmed: 27416987
Virulence. 2018 Dec 31;9(1):994-999
pubmed: 29667494
Euro Surveill. 2017 Sep;22(39):
pubmed: 29019312
Gut Pathog. 2020 Jan 27;12:5
pubmed: 32002025
Sci Rep. 2019 Feb 20;9(1):2392
pubmed: 30787414
S Afr Med J. 2016 Apr 19;106(5):35-6
pubmed: 27138657
Antimicrob Resist Infect Control. 2017 Jul 17;6:75
pubmed: 28725421
Front Cell Infect Microbiol. 2019 Mar 06;9:41
pubmed: 30895173
APMIS. 2018 May;126(5):413-417
pubmed: 29696722
Infect Drug Resist. 2019 Apr 29;12:1001-1010
pubmed: 31118706
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3249-50
pubmed: 26953204
Expert Rev Anti Infect Ther. 2018 Jun;16(6):443-446
pubmed: 29865881
Euro Surveill. 2016;21(9):30155
pubmed: 26967914
Front Microbiol. 2018 Sep 28;9:2299
pubmed: 30323797
Int J Infect Dis. 2017 Jan;54:77-84
pubmed: 27915108
Lancet Infect Dis. 2016 Mar;16(3):289-90
pubmed: 26973304
Lancet Infect Dis. 2016 Feb;16(2):147
pubmed: 26711360
Vet Microbiol. 2018 Jan;213:42-46
pubmed: 29292002
BMC Res Notes. 2018 Feb 20;11(1):143
pubmed: 29463301
Euro Surveill. 2018 Feb;23(6):
pubmed: 29439754
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172
Clin Lab. 2020 Mar 1;66(3):
pubmed: 32162864
J Pak Med Assoc. 2016 Sep;66(9):1068-1072
pubmed: 27654721
J Pak Med Assoc. 2018 Jun;68(6):893-897
pubmed: 30325907